一分钟看懂
这是一项关于MECP2 Duplication Syndrome的不适用研究，登记的药物或干预包括HG204，当前状态为招募中。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
HG204 · 不适用
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University First Hospital · 北京
公开的入选条件
- * Males ≥ 2 and ≤18 years at the time of signing informed consent;
- * Genetic test and clinical confirmed diagnosis of MDS;
- * Stable pattern of seizures, or has had no seizures while currently receiving medical treatment (including antiepileptics) and physical therapy are stable for at least 2 months before screening;
- * Willing to adhere to protocol, including biological samples collection and hospitalization for intracerebroventricular injection surgery;
- * Acceptable hematology, clinical chemistry, and urine laboratory parameters.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06615206；登记信息更新于 2024-11-26。